Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

Griet Hoste; Laurence Slembrouck; Lynn Jongen; Kevin Punie; Tom Matton; Sara Vander Borght; Isabelle Vanden Bempt; Johan Menten; Hans Wildiers; Giuseppe Floris; Carlos Arteaga; Patrick Neven

doi:10.1007/s40261-019-00748-x

Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

Griet Hoste, Laurence Slembrouck, Lynn Jongen, Kevin Punie, Tom Matton, Sara Vander Borght, Isabelle Vanden Bempt, Johan Menten, Hans Wildiers, Giuseppe Floris, Carlos Arteaga, Patrick Neven

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Conflict of interest, which previously read: The authors declare that they have no competing interests. Should read: Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.

Original language	English (US)
Pages (from-to)	113
Number of pages	1
Journal	Clinical Drug Investigation
Volume	39
Issue number	1
DOIs	https://doi.org/10.1007/s40261-019-00748-x
State	Published - Jan 31 2019
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1007/s40261-019-00748-x

Fingerprint

Dive into the research topics of 'Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)'. Together they form a unique fingerprint.

Cite this

Hoste, G., Slembrouck, L., Jongen, L., Punie, K., Matton, T., Vander Borght, S., Vanden Bempt, I., Menten, J., Wildiers, H., Floris, G., Arteaga, C., & Neven, P. (2019). Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3). Clinical Drug Investigation, 39(1), 113. https://doi.org/10.1007/s40261-019-00748-x

Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3). / Hoste, Griet; Slembrouck, Laurence; Jongen, Lynn et al.
In: Clinical Drug Investigation, Vol. 39, No. 1, 31.01.2019, p. 113.

Research output: Contribution to journal › Comment/debate › peer-review

Hoste, G, Slembrouck, L, Jongen, L, Punie, K, Matton, T, Vander Borght, S, Vanden Bempt, I, Menten, J, Wildiers, H, Floris, G, Arteaga, C & Neven, P 2019, 'Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)', Clinical Drug Investigation, vol. 39, no. 1, pp. 113. https://doi.org/10.1007/s40261-019-00748-x

Hoste G, Slembrouck L, Jongen L, Punie K, Matton T, Vander Borght S et al. Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3). Clinical Drug Investigation. 2019 Jan 31;39(1):113. doi: 10.1007/s40261-019-00748-x

Hoste, Griet ; Slembrouck, Laurence ; Jongen, Lynn et al. / Correction to : Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3). In: Clinical Drug Investigation. 2019 ; Vol. 39, No. 1. pp. 113.

@article{f1de5d8fdafd452591839ad9913f5d71,

title = "Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)",

abstract = "Conflict of interest, which previously read: The authors declare that they have no competing interests. Should read: Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.",

author = "Griet Hoste and Laurence Slembrouck and Lynn Jongen and Kevin Punie and Tom Matton and {Vander Borght}, Sara and {Vanden Bempt}, Isabelle and Johan Menten and Hans Wildiers and Giuseppe Floris and Carlos Arteaga and Patrick Neven",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Nature Switzerland AG.",

year = "2019",

month = jan,

day = "31",

doi = "10.1007/s40261-019-00748-x",

language = "English (US)",

volume = "39",

pages = "113",

journal = "Clinical Drug Investigation",

issn = "1173-2563",

publisher = "Adis International Ltd",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

AU - Hoste, Griet

AU - Slembrouck, Laurence

AU - Jongen, Lynn

AU - Punie, Kevin

AU - Matton, Tom

AU - Vander Borght, Sara

AU - Vanden Bempt, Isabelle

AU - Menten, Johan

AU - Wildiers, Hans

AU - Floris, Giuseppe

AU - Arteaga, Carlos

AU - Neven, Patrick

PY - 2019/1/31

Y1 - 2019/1/31

N2 - Conflict of interest, which previously read: The authors declare that they have no competing interests. Should read: Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.

AB - Conflict of interest, which previously read: The authors declare that they have no competing interests. Should read: Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.

UR - http://www.scopus.com/inward/record.url?scp=85060035354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060035354&partnerID=8YFLogxK

U2 - 10.1007/s40261-019-00748-x

DO - 10.1007/s40261-019-00748-x

M3 - Comment/debate

C2 - 30637612

AN - SCOPUS:85060035354

SN - 1173-2563

VL - 39

SP - 113

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

IS - 1

ER -

Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this